Search

everythinglearnresearchcommunity

for

Search:↓

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

JAK inhibitors are effective treatments for alopecia areata.

Finasteride increases P-glycoprotein activity in the liver and kidney.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Adding a second method to PROTACs could improve cancer treatment.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Presurgical models can effectively and affordably screen cancer prevention agents.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.

Avacopan is generally safe, with some minor side effects like nausea and fatigue.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Tacrolimus is a better option than cyclosporine due to fewer side effects.